William Blair upgraded Genmab (GMAB) to Outperform from Market Perform.Optimize Your Investment Research with SparkEffectively assess a stock's ...
As stipulated by the development and option agreement between Genmab and J&J for HexaBody-CD38, Genmab provided J&J with data from a clinical proof-of-concept study in multiple myeloma, including a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback